274 related articles for article (PubMed ID: 23751120)
1. Copper chaperone Atox1 interacts with the metal-binding domain of Wilson's disease protein in cisplatin detoxification.
Dolgova NV; Nokhrin S; Yu CH; George GN; Dmitriev OY
Biochem J; 2013 Aug; 454(1):147-56. PubMed ID: 23751120
[TBL] [Abstract][Full Text] [Related]
2. The N-terminal metal-binding site 2 of the Wilson's Disease Protein plays a key role in the transfer of copper from Atox1.
Walker JM; Huster D; Ralle M; Morgan CT; Blackburn NJ; Lutsenko S
J Biol Chem; 2004 Apr; 279(15):15376-84. PubMed ID: 14754885
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
4. Copper transfer to the N-terminal domain of the Wilson disease protein (ATP7B): X-ray absorption spectroscopy of reconstituted and chaperone-loaded metal binding domains and their interaction with exogenous ligands.
Ralle M; Lutsenko S; Blackburn NJ
J Inorg Biochem; 2004 May; 98(5):765-74. PubMed ID: 15134922
[TBL] [Abstract][Full Text] [Related]
5. Metallochaperone Atox1 transfers copper to the NH2-terminal domain of the Wilson's disease protein and regulates its catalytic activity.
Walker JM; Tsivkovskii R; Lutsenko S
J Biol Chem; 2002 Aug; 277(31):27953-9. PubMed ID: 12029094
[TBL] [Abstract][Full Text] [Related]
6. Dynamics and stability of the metal binding domains of the Menkes ATPase and their interaction with metallochaperone HAH1.
Arumugam K; Crouzy S
Biochemistry; 2012 Nov; 51(44):8885-906. PubMed ID: 23075277
[TBL] [Abstract][Full Text] [Related]
7. Binding of Copper and Cisplatin to Atox1 Is Mediated by Glutathione through the Formation of Metal-Sulfur Clusters.
Dolgova NV; Yu C; Cvitkovic JP; Hodak M; Nienaber KH; Summers KL; Cotelesage JJH; Bernholc J; Kaminski GA; Pickering IJ; George GN; Dmitriev OY
Biochemistry; 2017 Jun; 56(24):3129-3141. PubMed ID: 28549213
[TBL] [Abstract][Full Text] [Related]
8. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B.
Tadini-Buoninsegni F; Bartolommei G; Moncelli MR; Inesi G; Galliani A; Sinisi M; Losacco M; Natile G; Arnesano F
Angew Chem Int Ed Engl; 2014 Jan; 53(5):1297-301. PubMed ID: 24375922
[TBL] [Abstract][Full Text] [Related]
9. Platination of the copper transporter ATP7A involved in anticancer drug resistance.
Calandrini V; Arnesano F; Galliani A; Nguyen TH; Ippoliti E; Carloni P; Natile G
Dalton Trans; 2014 Aug; 43(31):12085-94. PubMed ID: 24983998
[TBL] [Abstract][Full Text] [Related]
10. Crystal structures of cisplatin bound to a human copper chaperone.
Boal AK; Rosenzweig AC
J Am Chem Soc; 2009 Oct; 131(40):14196-7. PubMed ID: 19807176
[TBL] [Abstract][Full Text] [Related]
11. Functional properties of the human copper-transporting ATPase ATP7B (the Wilson's disease protein) and regulation by metallochaperone Atox1.
Lutsenko S; Tsivkovskii R; Walker JM
Ann N Y Acad Sci; 2003 Apr; 986():204-11. PubMed ID: 12763797
[TBL] [Abstract][Full Text] [Related]
12. Determinants for simultaneous binding of copper and platinum to human chaperone Atox1: hitchhiking not hijacking.
Palm-Espling ME; Andersson CD; Björn E; Linusson A; Wittung-Stafshede P
PLoS One; 2013; 8(7):e70473. PubMed ID: 23936210
[TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of the interaction of the copper chaperone Atox1 with the metal binding sites of the Menkes protein.
Strausak D; Howie MK; Firth SD; Schlicksupp A; Pipkorn R; Multhaup G; Mercer JF
J Biol Chem; 2003 Jun; 278(23):20821-7. PubMed ID: 12679332
[TBL] [Abstract][Full Text] [Related]
14. Tetrathiomolybdate inhibits the reaction of cisplatin with human copper chaperone Atox1.
Tian Y; Fang T; Yuan S; Zheng Y; Arnesano F; Natile G; Liu Y
Metallomics; 2018 May; 10(5):745-750. PubMed ID: 29721562
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro.
Palm ME; Weise CF; Lundin C; Wingsle G; Nygren Y; Björn E; Naredi P; Wolf-Watz M; Wittung-Stafshede P
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6951-6. PubMed ID: 21482801
[TBL] [Abstract][Full Text] [Related]
16. Distinct Wilson's disease mutations in ATP7B are associated with enhanced binding to COMMD1 and reduced stability of ATP7B.
de Bie P; van de Sluis B; Burstein E; van de Berghe PV; Muller P; Berger R; Gitlin JD; Wijmenga C; Klomp LW
Gastroenterology; 2007 Oct; 133(4):1316-26. PubMed ID: 17919502
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
18. Platinum transfer from hCTR1 to Atox1 is dependent on the type of platinum complex.
Wu X; Yuan S; Wang E; Tong Y; Ma G; Wei K; Liu Y
Metallomics; 2017 May; 9(5):546-555. PubMed ID: 28383086
[TBL] [Abstract][Full Text] [Related]
19. Binding of copper(I) by the Wilson disease protein and its copper chaperone.
Wernimont AK; Yatsunyk LA; Rosenzweig AC
J Biol Chem; 2004 Mar; 279(13):12269-76. PubMed ID: 14709553
[TBL] [Abstract][Full Text] [Related]
20. Conformational dynamics of metal-binding domains in Wilson disease protein: molecular insights into selective copper transfer.
Rodriguez-Granillo A; Crespo A; Wittung-Stafshede P
Biochemistry; 2009 Jun; 48(25):5849-63. PubMed ID: 19449859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
